|
Chief Science Officer Director of Neurogenetics Core Despite our best efforts over the last few decades, currently available treatments for addiction are only modestly effective. My lab has taken a two pronged approach to address the limited effectiveness of current treatments.
To develop more effective therapies, I have focused on medications and/or psychosocial interventions that target the basic neurobiological and behavioral mechanisms that are involved in the development and maintenance of addiction. To determine which individuals are most vulnerable to addiction and to determine which individuals might benefit most from a given treatment, I have focused on genetic factors that might explain individual variation in the same basic neurobiological and behavioral mechanisms that influence the etiology of addiction. These foci yield valuable information about who may be most at risk for developing addiction, and yield valuable information about who may be most likely to respond favorably to a given treatment approach. Ultimately, matching individuals to treatment based on specific genetic variables has the promise of increasing the overall effectiveness of our treatment approaches. RESEARCH INTERESTS
SPECIFIC PROJECTS
FUTURE PROJECTS PUBLICATIONS
LAB ALUMS Vist the Colorado Alcohol and Smoking Lab For more information on the University of New Mexico's Center on Alcoholism, Substance Abuse, and Addictions (CASAA) LIGAND (Laboratory of Imaging Genomics and Neurodiagnostic Discovery)
Director
• Kent Hutchison, Ph.D. CV
Research Scientist
• Francesca Filbey, Ph.D. CV
Neurogenetics Lab Administrator
• Marilee Morgan, M.S. CV
Post-Doctoral Fellows
• Sarah Feldstein Ewing, Ph.D. CV
• Eric Claus, Ph.D. CV
Research Associates
• Jessie Otoski is a Program Project Manager who has been working at the Mind Research Network for three years. She graduated in 2004, from The University of New Mexico, with a B.S. in Biology and a minor in Chemistry. She is responsible for managing the Alcohol Dependency Treatment project. She is also responsible for coordinating the daily administrative activities of all of Dr. Hutchison's projects. • Melynda Byers graduated from the University of Colorado in Boulder in May 2007 with a B.A. in Molecular, Cellular, and Developmental Biology. She began working for Dr. Hutchison in June as the genetics RA for both the alcohol dependency treatment study and fMRI ethanol study. • Leah Vermont graduated from the University of New Mexico with a B.S. in Psychology and a minor in Biology. She is the research coordinator for the alcohol and neuroimaging project, ‘Alcohol Dependence: Integrating Genetic & fMRI Methods’ as well as for the cannabis research project, ‘The Effects of CNR1 on Brain Function in Cannabis Users’, headed by Francesca Filbey. • Aaron Losey graduated from Occidental College in Los Angeles in May 2006 with a B.A. in Kinesiology and a minor in Spanish Cultural Studies. He began working for Dr. Hutchison in January as a research associate for the Sensitivity to Intravenous Ethanol: Genetic Determinants study. • Samuel Kramer graduated from the University of New Mexico in December 2007 with a B.S. in Biological Anthropology and a B.S. in Psychology. He began working for Dr. Hutchison in January as a Research Associate for the Sensitivity to Intravenous Ethanol: Genetic Determinants study. • Maria Vahtel graduated in 2004 from St. John's College, Santa Fe, with an M.A. in Eastern Classics, and in 2001 from The University of New Mexico with a B.S. in Biological Anthropology/minor in Biology. She worked as a Medical Technologist for TriCore Reference Labs for three years before beginning as a Research Associate I for the Alcohol Dependency Treatment project in March 2008.
• Ursula Myers graduated in May 2007 from the University of New Mexico with a B.A. in Psychology and a minor in Criminology. She began working for Dr. Filbey as a research associate in April on the cannabis research project 'The Effects of CNR1 on Brian Function in Cannabis Users' as well as the tobacco research project 'Neurogenetic Determinants of Tobacco Initiation and Maintenance'.
• Lindsay Chandler graduated from the University of New Mexico in December 2007 with a B.A. in Psychology and a B.A. in Philosophy. She began working for Dr. Hutchison in April as a Research Associate for the Role of Neurocognition and Genetics in Adolescent Health Risk Behavior study. • Robert Chavez graduated from the University of New Mexico with a B.S. in Psychology and a minor in Statistics. He has worked at the Mind Research Network since January of 2007, and began working for Dr. Filbey lab in March of 2008. He is responsible for data and image analysis on the cannabis research project 'The Effects of CNR1 on Brian Function in Cannabis Users' and the tobacco research project 'Neurogenetic Determinants of Tobacco Initiation and Maintenance'. RESEARCH INTERESTS
Integrating Genetic and Neuroimaging Approaches
One very important aspect to our research is the notion that having well defined phenotypes that are proximal to the underlying biological mechanisms is critical to the success of efforts designed to uncover genetic variation that contributes to these phenotypes. In other words, a rudimentary phenotype like whether a person smokes cigarettes (or not) is unlikely to be useful in a genetic study because of the sheer number of factors that may influence that phenotype. Much of our research to date has focused on refining the phenotype such that a given phenotype will be useful in a genetic study. To date, we have focused on acute responses to alcohol, tobacco, and marijuana, publishing papers on pharmacological and genetic factors that influence these phenotypes. While acute responses to cues or the drugs themselves are useful phenotypes, we are currently working to develop phenotypes that are even more proximal to the neurobiology of addiction. We recently migrated our laboratory based phenotypes to a neuroimaging environment and are integrating this approach with our recent efforts at identifying genetic variation that influences gene expression in post-mortem tissue samples taken from brain regions that are critical to the neurobiology of addiction. Thus, the genetic approach should yield valuable information about genetic variation that alters gene expression in critical brain areas. The neuroimaging approach will allow us to examine whether this genetic variation also has an impact in vivo on brain activation in response to a drug or drug-related cues.
SPECIFIC PROJECTS
Alcohol & Neuroimaging
Craving can be reliably elicited in the laboratory with humans, is associated with alcohol dependence, and is a primary target of biological and behavioral interventions. Activation of mesolimbic and mesocortical structures has been implicated in the development and expression of craving for alcohol and other drugs. Dopamine (D4) receptors are localized to these same structures and our preliminary work has suggested that a D4 antagonist moderates the experience of craving after exposure to alcohol. Our previous research has also suggested that the DRD4 VNTR polymorphism is a genetic factor that influences alcohol-elicited craving. The aims of this project are to determine whether exposure to alcohol increases activation of mesolimbic and prefrontal brain structures using BOLD fMRI, to determine whether this activation is correlated with the subjective experience of craving, to identify genetic variation that influences this activation, and to identify medications that attenuate this activation. The successful completion of the research is also expected to advance our understanding of the role of genetic factors and lead to the development of pharmacotherapies that can be tailored to the individual based on genetic variation.
Treatment of Alcohol Dependence
Craving for alcohol has been related to loss of control drinking and is a major target of biological and behavioral interventions for alcohol dependence. Our previous research has demonstrated that a dopaminergic medication attenuates craving for alcohol, that a variant in the gene that expresses D4 receptors and a variant in the cannabinoid receptor gene influences craving for alcohol, and that a dopaminergic medication (olanzapine) is effective at reducing craving among individuals with this variant. Our current research will examine whether the effects of dopamine and cannabinoid medications on drinking outcomes are mediated by its effects on a specific putative mechanism (i.e., cue-elicited craving for alcohol) and determine whether the DRD4 VNTR polymorphism (or CNR1 variation) is a marker for the effectiveness of olanzapine. To that end, 202 alcohol dependent subjects will be randomly assigned to medication group and receive 12 weeks of medication. Subjects will complete follow-up assessments at 3 and 6 months after the end of the treatment. The successful completion of the proposed research is expected to advance medications for alcohol dependence and advance genetic markers that predict the effectiveness of these medications.
Infusion of Ethanol
The alcohol-related phenotypes that are commonly used in genetic studies are often based on broadly defined diagnostic criteria. We have focused our previous research on the development of intermediate phenotypes, or endophenotypes, that are more proximal to the biological mechanisms that underlie the etiology of alcohol dependence (e.g., acute effects of alcohol). The extant literature as well as our own previous studies clearly suggests that m opiate receptors and the m opiate receptor gene (OPRM1) are important in terms of the acute effects of alcohol. Likewise, our preliminary data indicate that cannabinoid (CB1) receptors and the cannabinoid receptor gene (CNR1) strongly influence affective responses to alcohol. The first aim of the proposed research is to replicate and extend our previous research by testing whether a functional SNP (A118G) in the OPRM1 influences the effects of an acute infusion of alcohol, as compared to a saline infusion, on physiological and subjective measures of stimulation, sedation, and mood. The first aim will also test whether this effect is specific to alcohol dependent individuals by comparing alcohol dependent individuals with healthy, non-dependent drinkers. The second aim will replicate and extend our research on the CNR1 by testing whether a functional SNP in the CNR1 influences acute responses to alcohol and whether this effect is more pronounced among alcohol dependent individuals. Finally, the third aim will examine the additive effects of these two SNPs. The proposed study is designed to both build on the strengths and address the limitations of our previous work by utilizing an alcohol infusion protocol (i.e., clamping protocol) to reduce unwanted pharmacokinetic and pharmacodynamic variability across individuals, thereby improving the overall power to detect the effects of the genetic variants and their interaction. In addition, the proposed research will address the limitations of our previous work by using a saline control condition and by testing both alcohol dependent and healthy non-dependent controls. These design improvements will allow us to examine whether or not the effect of genetic variants in the OPRM1 and CNR1 have an immediate effect on responses to alcohol or whether these variants interact with repeated exposure to alcohol to produce an enhanced sensitivity to the effects of alcohol (i.e., a gene by environment interaction) that is more evident in alcohol dependent individuals.
Cannabis Research
Despite rapid advances in our understanding of the human genome, the identification of genetic factors that influence the etiology and treatment of alcohol and drug abuse has yet to materialize. One reason for the lack of progress is poorly defined, poorly measured, ambiguous, and/or rudimentary phenotypes (e.g., dichotomous diagnostic variables) that inherently limit our ability to detect the influence of genetic factors. One area of substance abuse research that is especially deficient with respect to phenotypic definition, measurement, and operationalization is research on cannabis abuse. Three constructs that are clearly important in terms of the etiology and treatment of a variety of drugs of abuse are withdrawal, craving, and sensitivity to the acute effects of the drug. The current application proposes to assess these cannabis-related phenotypes in the context of both cross-sectional and longitudinal designs to advance our understanding of the genetic, biological, and behavioral determinants of cannabis use and abuse. Two separate studies are proposed to address the primary aims of the project. Study 1 will define and characterize the validity of several phenotypes, including withdrawal, cue-elicited craving, and sensitivity to the rewarding effects of cannabis in a cross-sectional sample of infrequent versus frequent cannabis smokers. Study 2 will characterize the trajectory of these phenotypes using latent growth modeling in the context of a 2 year longitudinal investigation of individuals who smoked infrequently at the beginning of the study. The proposed research will also test whether these phenotypes are moderated by single nucleotide polymorphisms (SNPs) in the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes. The proposed research is expected to lay the foundation for future research on the genetic factors that underlie the progression of cannabis use and abuse.
FUTURE PROJECTS
Tobacco Research
One of the primary mechanisms underlying the addictive nature of tobacco use is the binding of nicotine to nicotinic acetycholine receptors (nAChRs). The a4 subunit of the nicotinic receptor is highly expressed in the central nervous system and plays a major role in the cognitive effects of nicotine as well as tolerance, reward, and the modulation of mesolimbic dopamine function, all of which are critical to the development of tobacco dependence. Given the importance of the a4 subunit, the gene that expresses this subunit (CHRNA4) is a prime target for research into the genetic factors that influence tobacco dependence. Our preliminary research indicates that there are three single nucleotide polymorphisms (SNPs) that alter expression in cell culture models and change subjective sensitivity to nicotine in a human laboratory paradigm. To better understand the role of this gene and to address the limitations of previous work, we will develop an integrative approach with the following specific aims and hypotheses. The first aim is to utilize a neuroimaging approach to examine activation of brain structures after exposure to alcohol cues. The second aim to determine with a medication that targets this receptor (varenicline) reduces activation of these brain structures and whether varenicline is more effective based on genetic variation at these loci. PUBLICATIONS A. Selected peer-reviewed publications (in chronological order).
1. Frank, M.J., Moustafa, A.A., Haughey, H.M., Curran, T., & Hutchison, K.E. (2007). Genetic triple dissociation reveals multiple roles for dopamine in reinforcement learning. Proceedings of the National Academy of Sciences, 104, 16311-6.
2. McClernon, F.J., Hutchison, K.E., Rose, J.E., & Kozing, R.V. (in press). DRD4 VNTR polymorphism is associated with transient fMRI-BOLD responses to smoking cues. Psychopharmacology.
3. Ray, L., Rhee, S.H., Stallings, M.C., Knopik, V., & Hutchison, K.E. (2007). Examining the heritability of a laboratory-based smoking endophenotype: Initial Results from an experimental twin study. Twin Research and Human Genetics, 10, 546-53.
4. Tanabe, J., Crowley, T., Hutchison, K.E., Miller, D., Johnson, G., Du, Y., Zerbe, G., & Freedman, R. (in press). Ventral striatal blood flow is altered by acute nicotine but not withdrawal from nicotine. Neuropsychopharmacology.
5. Ray, L., Miranda, R., Kahler, C., Leventhal, A., Monti, P., Swift, R., & Hutchison, K.E. (2007). Pharmacological Effects of Naltrexone and Intravenous Alcohol on Craving for Cigarettes among Light Smokers: A Pilot Study. Psychopharmacology, 193, 449-56.
6. van den Wildenberg, E, Janssen, R, Hutchison, K.E., van Breukelen, G., & Weirs, R.W. (in press). Polymorphisms of the dopamine D4 receptor gene (DRD4 VNTR) and cannabinoid receptor gene (CNR1) are not strongly related to cue-reactivity after alcohol exposure. Addiction Biology.
7. Helstrom, A., Hutchison, K.E., & Bryan, A. (in press). Motivational enhancement therapy for high-risk adolescent smokers. Addictive Behaviors.
8. Hutchison, K.E., Allen, D., Jepson, C., Lerman, C., Benowitz, N., Stitzel, J., Bryan, A., McGeary, J., & Haughey, H.M. (2007). CHRNA4 and Tobacco Dependence: From Gene Regulation to Treatment Outcome. Archives of General Psychiatry, 64, 1078-86.
9. Ray, L.A. & Hutchison, K.E. (2007). Effects of Naltrexone on Alcohol Sensitivity and Genetic Moderators of Medication Response: A Double-Blind Placebo-Controlled Study. Archives of General Psychiatry, 64, 1069-77.
10. Tanabe, J., Thompson, L., Claus, E., Dalwani, M., Hutchison, K., & Banich, M.T. (2007). Prefrontal cortex activity is reduced in gambling and non-gambling substance users during decision-making. Human Brain Mapping, 28, 1276-86..
11. Ray, L.A., Meskew-Stacer, S., & Hutchison, K.E. (2007). The relationship between prospective self-rating of alcohol sensitivity and craving and experimental results from two alcohol challenge studies. Journal of Studies on Alcohol, 68, 379-84.
12. Rohsenow, D. J., Monti, P. M., Hutchison, K.E., Swift, R. S., MacKinnon, S. V., Sirota, A. D., & Kaplan, G. B. (2007). Naltrexone and high dose transdermal nicotine: Effects on nicotine withdrawal, urges, smoking, and effects of smoking. Experimental and Clinical Psychopharmacology, 15, 81-92.
13. Bryan, A., Hutchison, K.E., Seals, D.S., & Allen, D.L. (2007). A transdisciplinary model integrating genetic, physiological, and psychological correlates of voluntary exercise. Health Psychology, 26, 30-39.
14. Ray, L.A., Bryan, A., & Hutchion, K.E. (2006). Psychosocial predictors of treatment outcome, dropout, and change processes in a pharmacological clinical trial for alcohol dependence. Addiction Disorders & Their Treatment, 5, 179-190.
15. Ray, L.A., McGeary, J.M., Marshall, E., & Hutchison, K.E. (2006). Risk factors for alcohol misuse: Examining heart rate reactivity to alcohol, alcohol sensitivity, and personality constructs. Addictive Behaviors, 31, 1959-1973.
16. Hutchison, K.E., Ray, L., Sandman, E., Rutter, M-C, Peters, A., Davidson, D., & Swift, R. (2006). The Effect of Olanzapine on Craving and Alcohol Consumption, Neuropsychopharmacology, 31(6), 1310-1317.
17. Mahaffey, A.L., Bryan, A., & Hutchison, K.E. (2005). Startle eyeblink as a potential implicit measure of homophobia. Basic and Applied Social Psychology, 27, 37-45.
18. Hines, L., Ray, L., Hutchison, K.E., & Tabakoff, B. (2005). Alcoholism: The dissection for endophenotypes. Dialogues in Clinical Neuroscience, 7, 153-165.
19. Giargiari, T., Mahaffey, A.L., Craighead, E., & Hutchison, K.E. (2005). Affective Responses to Sexual Stimuli Are Attenuated Among Individuals with Low Levels of Sexual Desire. Archives of Sexual Behavior, 34(5): 547-56
20. Ilgen, M. & Hutchison, K.E. (2005). A History of Major Depressive Disorder and the Response to Stress. Journal of Affective Disorders, 86, 143-150.
21. Sobik, L., Hutchison, K.E., & Craighead, L. (2005). Cue-elicited craving for food: a fresh approach to the study of binge eating. Appetite, 44, 253-261.
22. Mahaffey, A.L., Bryan, A., & Hutchison, K.E. (2005). Gender differences in affective responses to homoerotic stimuli: Evidence for an unconscious bias among men. Archives of Sexual Behavior, 34(5): 547-56.
23. Bryan, A., Rocheleau, C.A., Robbins, R.N., & Hutchison, K.E. (2005). Condom use among high-risk adolescents: Testing the influence of alcohol use on the relationship of cognitive correlates of behavior. Health Psychology,24(2): 133-42.
24. Hutchison, K.E., Niaura, R., Swift, R., Rutter, M.C., Sobik, L. (2004). Olanzapine attenuates cue-elicited craving for tobacco. Psychopharmacology, 175, 407-413.
25. Ray, L. & Hutchison, K.E. (2004). A polymorphism of the μ-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcoholism: Clinical and Experimental Research, 28, 1789-1795.
26. Fromme, K., de Wit, H., Hutchison, K.E., Ray, L., Corbin, W.R., Cook, T.A.R., Wall, T.L., & Goldman, D. (2004). Biological and Behavioral Markers of Alcohol Sensitivity. Alcoholism: Clinical and Experimental Research, 28, 247-256.
27. Hutchison, K.E., Stallings, M., McGeary, J.M., & Bryan, A. (2004). Population stratification in the case-control design: Fatal threat or red herring? Psychological Bulletin, 130, 66-79.
28. Helstrom, A., Bryan, A., Hutchison, K.E., Riggs, P.D., & Blechman, E.A. (2004). Tobacco and Alcohol Use Mediate the Association Between Externalizing Behavior and Illicit Drug Use Among Adolescents. Prevention Science, 5, 267-77.
29. David, S.P., Niaura, R.S., Papandonatos, G.D., Shadel, W.G., Burkholder, G.J., Britt, D.M., Day, A., Stumpff, J., Hutchison, K., Murphy, M., Johnstone, E.., Griffiths, S., Walton, R.T. (2003). Does the DRD2-Taq1 A polymorphism influence treatment response to buproprion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine and Tobacco Research, 5, 1-8.
30. Hutchison, K.E., Wooden, A., Swift, R., McGeary, J., Adler, L., Paris, L. (2003). Olanzapine reduces craving for alcohol: A DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology, 28, 1882-1888.
31. Hutchison, K.E., McGeary, J., Wooden, A., Blumenthal, T., & Ito, T. (2003). Startle Magnitude and Prepulse Inhibition: Effects of Alcohol and Attention, Psychopharmacology, 167, 235-41.
32. Davidson, D., Hutchison, K.E., Dagon, C., & Swift, R.M. (2002). Assessing the Incentive-Rewarding Psychomotor Stimulant Effects of Alcohol in Humans. Pharmacology, Biochemistry, & Behavior, 72, 151-156.
33. Hutchison, K.E., LaChance, H., Niaura, R., Bryan, A.D., & Smolen, A. (2002). The DRD4 VNTR polymorphism influences reactivity to smoking cues. Journal of Abnormal Psychology, 111, 134-143.
34. Hutchison, K.E., McGeary, J., Smolen, A., Bryan, A.D., & Swift, R.M. (2002). The DRD4 VNTR polymorphism moderates craving after alcohol consumption. Health Psychology, 21, 139-146.
35. Hutchison, K.E., Swift, R.M., Rohsenow, D.J., Monti, P.M., Davidson, D., & Almeida, A. (2001). Olanzapine Reduces Urge to Drink After Drinking Cues and a Priming Dose of Alcohol. Psychopharmacology, 155, 27-34.
36. Rohsenow, D.J., Monti, P.M., Hutchison, K.E., Swift, R.M., & Colby, S.M. (2000). Naltrexone's effects on reactivity to alcohol cues among alcoholic men. Journal of Abnormal Psychology, (109), 738-742.
37. Niaura, R., Shadel, W.G., Goldstein, M.G., Hutchison, K.E., & Abrams, D.B. (2001). Individual differences in responses to the first cigarette following overnight abstinence in regular smokers. Nicotine & Tobacco Research, 3, 37-44.
38. Hutchison, K.E., Niaura, R., & Swift, R. (2000). The Effects of Smoking High Nicotine Cigarettes on Prepulse Inhibition, Startle Latency, and Subjective Responses. Psychopharmacology, 150, 244-252.
39. Spencer, R. & Hutchison, K.E. (1999). Alcohol, Aging, and the Stress Response. Alcohol Research & Health, 23, 272-283.
40. Palfai, T., Monti, P.M., Ostafin, B. & Hutchison, K.E. (2000). Effects of nicotine deprivation on alcohol-related information processing and drinking behavior. Journal of Abnormal Psychology, 109, 96-105.
41. Shadel, W.G., Niaura, R., Brown, R., Hutchison, K.E., Abrams, D. (2001). A content analysis of smoking craving. Journal of Clinical Psychology, 57, 145-150.
42. Monti, P.M., Rohsenow, D.J., & Hutchison, K.E. (2000). Toward bridging the gap between biological, psychobiological, and psychosocial models of alcohol craving. Addiction, 95, Suppl 2, S229-S236.
43. Goulden, L.C., Collins, F.L., & Hutchison, K.E. (2000). Effects of dose and interdose interval on conditioned heart rate tolerance to smoking. Experimental and Clinical Psychopharmacology, 8, 142-146
44. Hutchison, K.E., Wood, M., Swift, R. (1999). Personality factors moderate subjective and psychophysiological responses to d-amphetamine in humans. Experimental and Clinical Psychopharmacology, 7, 493-501.
45. Monti, P.M., Rohsenow, D.J., Hutchison, K.E., et al., (1999). Naltrexone’s effects on cue-elicited craving among alcoholics in treatment. Alcoholism: Clinical and Experimental Research, 23, 1386-1394.
46. Hutchison, K.E, Niaura, R., & Swift, R. (1999). Smoking cues decrease prepulse inhibition of the startle response and increase craving. Experimental and Clinical Psychopharmacology, 7, 250-256.
47. Hutchison, K.E. & Swift, R. (1999). Effect of d-Amphetamine on Prepulse Inhibition of the Startle Reflex in Humans. Psychopharmacology, 143, 394-400.
48. Hutchison, K.E., Monti, P., Rohsenow, D., Swift, R., Colby, S., Niaura, R., & Gnys, M.A. (1999). Effects of naltrexone and nicotine replacement on smoking cue reactivity. Psychopharmacology, 142, 139-143.
49. Hutchison, K.E., Rohsenow, D., Monti, P., Palfai, T., & Swift, R. (1997). Prepulse Inhibition of the startle reflex: Preliminary results on the effects of a low dose of alcohol. Alcoholism: Clinical and Experimental Research, 21, 1312-1319.
50. Hutchison, K.E., Collins, F.L., Tassey, J.R., & Rosenberg, E. (1996). Stress, naltrexone, and the reinforcement value of nicotine. Experimental and Clinical Psychopharmacology, 4, 431-437. LAB ALUMS
Graduate Students
Dr. Lara Ray
Completed her internship at Brown University in 2007; Currently a post-doctoral fellow at Brown University and has an offer for an Assistant Professor position at Northwestern University.
Dr. Tracy Giargiari
Currently is a Senior Manager of Clinical Development at Elan Pharmaceuticals
Dr. Mark Ilgen
Completed internship at the Palo Alto VAMC in 2003;
Currently is an Assistant Professor at the University of Michigan
Dr. Amy Helstrom
Completed internship at the Boston Consortium in 2003;
Currently is an Assistant Professor at Boston University Dr. John McGeary
Completed internship at Brown University in 2003;
Currently is an Assistant Professor at Brown University
Dr. Heather LaChance
Completed internship at Harvard Medical School/Brockton VA in 2004 and post-doctoral fellowship at Brown University;
Currently is an Assistant Professor of Medicine, National Jewish Medical Center Post-doctoral
Dr. Laura Sobik
Completed her internship at Texas Women’s University; Currently a psychology resident at James Madison University
Undergraduate Students
Frank Kunik
Received UROP funding, graduated Magna Cum Laude, 2000
Vinnie Darkangelo
Received UROP funding, graduated Magna Cum Laude, 2000
John Atkins
Graduated Cum Laude, 2000, currently serving with the 82nd Airborne out of Fort Bragg
Erin Jurich
Received UROP funding, gradated Magna Cum Laude, 2002, currently in her 3rd year of the Neuropsych PsyD program at the University of Denver
Aileen Hartzel
Graduated Magna Cum Laude, 2003
Ashleigh Golub
Graduated Suma Cum Laude, 2004
Delaney Keefe
Graduated Magna Cum Laude, 2004
Ginger Kite
Graduated Magna Cum Laude, 2004
Michael Levin
Received UROP funding, graduated Suma Cum Laude, 2005, currently a graduate student at the University of Nevada
Former Research Associates and Project Managers
Rae Hicks
Received UROP funding, graduated Magna Cum Laude, 1999, completed her Ph.D. in the clinical psychology program at Syracuse University.
Aaron Grossberg
Received UROP funding, graduated Suma Cum Laude, 2002, currently a graduate student in the M.D./Ph.D. program at the University of Oregon.
Erin Marshall
Graduated Magna Cum Laude, 2004, worked in the lab full-time for 1 year, currently a graduate student in the clinical psychology program at the University of Vermont.
Rex Villanueva
Worked in the lab full-time for approximately 2 years. Currently enrolled in the Biomedical Sciences Masters Program at the University of Medicine and Dentistry of New Jersey.
Patrick Finan
Worked in the lab full-time for approximately 3 years, currently enrolled in the clinical psychology program at Arizona State University.
Marie-Christine Rutter
Worked in the lab full-time for approximately 2 years, currently enrolled in the counseling psychology program at Arizona State University.
Erica Sandman
Undergraduate research assistant for 1 year and graduated Cum Laude 2002. Worked full-time in the lab for approximately 2 years then went on for her Master's Degree in Social/Developmental Psychology at Brandeis University and completed in August 2005.
Emily Fisher
Project coordinator for treatment study; currently entertaining offers of graduate school in clinical psychology |
